Aurigene Pharmaceutical Inaugurated Advanced Biologics Facility
A subsidiary of Dr Reddy’s Laboratories Ltd, Aurigene Pharmaceutical Services Ltd, has inaugurated a new biologics facility in Genome Valley, Hyderabad. Spanning 70,000 sq ft, this facility specializes in process and analytical development, catering to preclinical and early-phase clinical trials for antibodies and recombinant proteins.
Process and analytical development labs are already functional, with manufacturing set to begin later in 2024. The facility features advanced equipment and skilled personnel for a seamless transition into commercial operations.
This addition complements the company’s existing capabilities, focusing on a range of recombinant proteins like monoclonal antibodies and antibody-drug conjugates. With this facility, the company offers end-to-end services, including compliant cell lines, process development, and analytical methods. These services target customers seeking rapid progress in clinical development. Akhil Ravi, CEO, Aurigene Pharmaceutical Services Ltd, stated that the strategic importance of this expansion is to advance biologics and enhance global customer service.